| 25-5147 |
Mingguo Cho v. Donald J. Trump, President of the United States, et al. |
Second Circuit |
2025-07-18 |
Denied |
IFP |
citizens-rights constitutional-rights emergency-use-authorization fda-approval judicial-review medical-facts |
JUDGEMENTS WITHOUT VERIFICATION OF THE PLAINTIFF'S MEDICAL FACTS.
Plaintiff had filled LAWSUIT many times and cases, trying to solve the big problems… |
| 24-294 |
Norwich Pharmaceuticals Inc. v. Salix Pharmaceuticals, Ltd., et al. |
Federal Circuit |
2024-09-13 |
Denied |
|
fda-approval generic-drugs hatch-waxman-act injunctive-relief patent-law statutory-interpretation |
Whether 35 U.S.C. § 271(e)(4)(A) requires courts to issue overly broad injunctive orders that delay FDA approval of generic drug applications beyond t… |
| 23-395 |
Alliance for Hippocratic Medicine, et al. v. Food and Drug Administration, et al. |
Fifth Circuit |
2023-10-16 |
Denied |
Amici (3) |
abortion abortion-medication administrative-procedure-act drug-regulation fda fda-approval generic-drugs medical-safety mifepristone subpart-h |
Whether Cross-Petitioners' challenge to FDA's 2000 mifepristone approval is timely |
| 22-37 |
Teva Pharmaceuticals USA, Inc. v. GlaxoSmithKline LLC, et al. |
Federal Circuit |
2022-07-13 |
Denied |
CVSGAmici (5)Relisted (3) |
active-inducement fda-approval generic-drug generic-drugs hatch-waxman-act inducement-doctrine patent-infringement skinny-label |
Whether a generic drug manufacturer can be held liable for inducing infringement of a patent on a use that its FDA-approved label has expressly carved… |
| 20-1572 |
Ramon D. Johnson, II v. Novartis Pharmaceuticals Corporation, et al. |
Fifth Circuit |
2021-05-13 |
Denied |
Response WaivedRelisted (2) |
brand-name-liability brand-name-manufacturer FDA-approval generic-drug generic-drug-liability label-defect leave-to-amend preemption product-liability state-law-claims texas-presumption-of-no-liability unapproved-indication |
Whether a brand name drug manufacturer can be held liable for the defective label of a generic drug product |
| 20-779 |
Argentum Pharmaceuticals LLC v. Novartis Pharmaceuticals Corporation |
Federal Circuit |
2020-12-08 |
Denied |
Amici (1)Response RequestedResponse WaivedRelisted (2) |
administrative-proceeding article-iii-standing article-three-standing fda-approval inter-partes-review joint-venture leahy-smith-america-invents-act patent-challenge patent-validity pharmaceutical-industry pharmaceutical-patent |
Did the Federal Circuit categorically and erroneously preclude redress for injured members of joint ventures in the pharmaceutical industry by only re… |
| 20-295 |
Hi-Tech Pharmaceuticals, Inc., et al. v. Food and Drug Administration, et al. |
Eleventh Circuit |
2020-09-08 |
Denied |
Response Waived |
botanical-ingredients constituent-definition dietary-supplements dmaa DSHEA FDA-approval federal-food-drug-and-cosmetic-act geranium-plants prior-history-of-use trace-quantities |
Whether a substance that naturally occurs in a plant is a 'constituent' of an 'herb or other botanical' under the Dietary Supplement Health and Educat… |
| 18-182 |
AIDS Healthcare Foundation, Inc. v. Gilead Sciences, Inc., et al. |
Federal Circuit |
2018-08-09 |
Denied |
Response Waived |
actual-controversy article-iii declaratory-judgment drug-exclusivity fda-approval generic-drugs patent-invalidity pharmaceutical pharmaceutical-patents standing |
Whether the 'actual controversy' requirement of the Declaratory Judgment Act requires a party seeking to introduce a generic drug product to file an a… |